NPM1 and DNMT3A mutations are associated with distinct blast immunophenotype in acute myeloid leukemia

0013399 2023 RIV US eng J
Kuželová, Kateřina^G - Brodská, Barbora - Marková, Jana - Petráčková, Martina - Schetelig, J. - Ransdorfová, Šárka - Gašová, Zdenka - Šálek, Cyril
NPM1 and DNMT3A mutations are associated with distinct blast immunophenotype in acute myeloid leukemia.
OncoImmunology. Vol. 11, no. 1 (2022), art. no. e2073050. ISSN 2162-4011
Institucionální podpora: RVO:00023736
Klíčová slova: AML * immunophenotype * NPM1 mutation * DNMT3A mutations * Tim-3
Cite Score: 12.500, rok: 2022; SJR: 2.003, rok: 2022; IF: 7.2, rok: 2022
DOI: 10.1080/2162402X.2022.2073050

Anotace: The immune system is important for elimination of residual leukemic cells during acute myeloid leukemia (AML) therapy. Anti-leukemia immune response can be inhibited by various mechanisms leading to immune evasion and disease relapse. Selected markers of immune escape were analyzed on AML cells from leukapheresis at diagnosis (N = 53). Hierarchical clustering of AML immunophenotypes yielded distinct genetic clusters. In the absence of DNMT3A mutation, NPM1 mutation was associated with decreased HLA expression and low levels of other markers (CLIP, PD-L1, TIM-3).